Theory Paper IIDrNB Cardiology – Theory Notes

ASPIRIN FOR PRIMARY PREVENTION AND LANDMARK EVIDENCE

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

ITHE PARADIGM SHIFT: FROM UNIVERSAL USE TO SELECTIVE BLEEDING AVOIDANCE

  • Historical Context vs. Modern Reality: Early primary-prevention aspirin trials conducted in the 1980s and 1990s (Physicians’ Health Study, HOT, Thrombosis Prevention Trial) enrolled cohorts with high smoking rates, untreated blood pressure, and minimal statin use. In the contemporary era of widespread high-intensity statin therapy, strict blood pressure control, and declining smoking rates, baseline incident ASCVD event rates have fallen substantially.
  • The Neutralized Net Clinical Benefit: While low-dose Aspirin (75 to 100 mg daily, irreversibly acetylating platelet COX-1 at Serine-529 to block Thromboxane A2 synthesis) produces a modest 10 to 12 percent relative risk reduction in non-fatal ischemic events, it simultaneously causes a 30 to 50 percent relative increase in major gastrointestinal and intracranial hemorrhage (by inhibiting gastric mucosal cytoprotective prostaglandin E2/prostacyclin). In low-to-moderate risk primary prevention, the Number Needed to Treat (NNT) to prevent one ischemic event approximates or exceeds the Number Needed to Harm (NNH) to cause one major bleed, eliminating net clinical benefit and zeroing out any all-cause or cardiovascular mortality reduction.

IICONTEMPORARY GUIDELINE RECOMMENDATIONS (ACC/AHA 2019, ESC 2021, AND USPSTF 2022)

Guideline Body Target Age & Clinical Group Class / Grade of Recommendation Specific Clinical Guidance
2019 ACC/AHA Primary Prevention Guidelines Adults Aged 40 to 70 Years at Higher ASCVD Risk & NO Increased Bleeding Risk Class IIb (Level A) — May Be Considered Low-dose Aspirin (75–100 mg/d) may be considered selectively in higher-risk adults (e.g., 10-yr ASCVD risk >=10–20%, CAC >=100, or uncontrolled risk factors)
2019 ACC/AHA Primary Prevention Guidelines Adults Aged >70 Years (Routine Primary Prevention) Class III: Harm (Level B-R) — Do Not Administer Routine low-dose Aspirin is contraindicated for primary prevention in adults >70 years old (ASPREE Trial)
2019 ACC/AHA Primary Prevention Guidelines Adults of ANY Age at Increased Risk of Bleeding Class III: Harm (Level C-LD) — Do Not Administer Contraindicated in prior GI bleed/peptic ulcer, thrombocytopenia, coagulopathy, CKD, or concurrent NSAIDs, steroids, or anticoagulants
2022 USPSTF Recommendation Adults Aged 40–59 Years (>=10% 10-yr risk) vs. Adults >=60 Years Grade C (Age 40–59 yr); Grade D — Against Initiating (Age >=60 yr) Individualized shared decision at age 40–59 yr; do not initiate primary-prevention aspirin at age 60 years or older
2021 ESC Prevention / 2023 ESC Diabetes Guidelines Diabetes Mellitus Without Symptomatic ASCVD Class IIb (Level A) in High/Very-High Risk DM; Class III in Low/Moderate Risk Aspirin (75–100 mg/d) may be considered in DM at high/very-high risk in the absence of clear contraindications (ASCEND Trial)

IIITHE 2018 LANDMARK “EVIDENCE TRINITY” (ARRIVE, ASCEND, AND ASPREE TRIALS)

  • The ARRIVE Trial (Lancet 2018 — Moderate-Risk Non-Diabetic Adults):
  • Population and Design: Randomized 12,546 non-diabetic adults (men >=55 yr, women >=60 yr) with an estimated moderate 10-year cardiovascular risk (10 to 20 percent; actual observed 10-year event rate was lower at ~8 to 9 percent due to contemporary BP/statin therapy) to enteric-coated Aspirin 100 mg daily vs. Placebo for a median of 5 years.
  • Results: Aspirin did NOT reduce the primary composite endpoint of CV death, MI, unstable angina, stroke, or TIA (4.29 percent vs. 4.48 percent; HR 0.96; p = 0.60), while more than doubling gastrointestinal bleeding (0.97 percent vs. 0.46 percent; HR 2.11; p = 0.0007).
  • The ASCEND Trial (NEJM 2018 — Primary Prevention in Diabetes Mellitus):
  • Population and Design: Randomized 15,480 adults (aged >=40 years) with Diabetes Mellitus and no evident cardiovascular disease to Aspirin 100 mg daily vs. Placebo for a mean of 7.4 years.
  • Results: Aspirin significantly reduced serious vascular events by 12 percent (8.5 percent vs. 9.6 percent; Rate Ratio 0.88; p = 0.01; absolute risk reduction 1.1 percent); however, it simultaneously increased major bleeding events by 29 percent (4.1 percent vs. 3.2 percent; Rate Ratio 1.29; p = 0.003; absolute risk increase 0.9 percent)—meaning the absolute ischemic reduction (NNT = 91) was almost completely counterbalanced by the absolute major bleeding increase (NNH = 112).
  • The ASPREE Trial (NEJM 2018 — Healthy Older Adults Aged >=70 Years):
  • Population and Design: Randomized 19,114 healthy community-dwelling older adults (aged >=70 years, or >=65 years among US Black and Hispanic participants) free of cardiovascular disease, dementia, or physical disability to Aspirin 100 mg daily vs. Placebo for a median of 4.7 years.
  • Results: Aspirin failed to prolong disability-free survival (the primary composite of death, dementia, or persistent physical disability) and failed to significantly reduce cardiovascular disease (HR 0.95), while causing a 38 percent relative increase in major hemorrhage (3.8 percent vs. 2.8 percent; HR 1.38; p < 0.001, including higher intracranial bleeding) and an unexpected higher all-cause mortality (5.9 percent vs. 5.2 percent; HR 1.14), a secondary finding to be interpreted with caution, driven mainly by cancer-related deaths in this elderly cohort.

IVCORONARY ARTERY CALCIUM (CAC) AS THE IMAGING TIE-BREAKER AND THE INDIAN CONTEXT

  • The MESA CAC Tie-Breaker Rule (Cainzos-Achirica et al., Circulation 2020): In asymptomatic primary-prevention adults aged 40 to 70 years without high bleeding risk, Coronary Artery Calcium (CAC) scoring accurately separates those harmed versus helped by Aspirin:
  • CAC = 0 (and CAC 1 to 99): The 10-year number needed to harm from major bleeding is far lower than the number needed to treat (Net Harm); Aspirin should be strictly withheld when CAC = 0.
  • CAC >= 100 Agatston Units (and Especially CAC >= 300 or >= 400): Signifies substantial subclinical atherosclerotic plaque burden where the absolute 5-year MACE reduction exceeds the major bleeding risk (Net Clinical Benefit), making low-dose Aspirin (75 to 100 mg/day) a reasonable (Class IIb) addition to high-intensity statin therapy.
  • Elevated Lipoprotein(a) Subgroup (ASPREE & Women’s Health Study Genotyping): Post-hoc genetic analyses suggest that primary-prevention individuals carrying high-risk LPA genotypes or severely elevated Lipoprotein(a) (>50 to 70 mg/dL) may derive a significant reduction in MACE from low-dose Aspirin without net harm.
  • Practical Application in the Indian Clinical Context:
    • Avoiding Reflex Aspirin in Uncomplicated Diabetes: Despite the high prevalence of Type 2 Diabetes in India, routine Aspirin is NOT indicated based on diabetes alone; foundational primary prevention in Indian diabetics relies on High-Intensity Statins, SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Blood Pressure Control.
    • High Endemic H. pylori and OTC NSAID GI Bleeding Risk: Because Indian patients have a high prevalence of Helicobacter pylori gastritis/peptic ulcer disease and frequent unmonitored use of over-the-counter NSAIDs, co-prescription of a Proton Pump Inhibitor (PPI) should be considered whenever low-dose Aspirin is initiated in high-risk primary-prevention patients (e.g., age 40 to 59 years with CAC >=100 or non-obstructive plaque on CCTA).

Key references

  • Arnett DK, Blumenthal RS, Albert MA, et al.: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, Circulation, 2019.
  • ASCEND Study Collaborative Group (Bowman L, Mafham M, Wallendszus K, et al.): Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus, New England Journal of Medicine, 2018.
  • Gaziano JM, Brotons C, Coppolecchia R, et al. (ARRIVE Executive Committee): Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial, The Lancet, 2018.
  • McNeil JJ, Wolfe R, Woods RL, et al. (ASPREE Investigator Group): Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly, New England Journal of Medicine, 2018.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.